Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes. [electronic resource]
Producer: 20170612Description: E643-E651 p. digitalISSN:- 1522-1555
- 3T3-L1 Cells
- Adipocytes -- drug effects
- Adipokines -- metabolism
- Adiponectin -- metabolism
- Animals
- Benzamides -- pharmacology
- Blood Glucose -- drug effects
- Chemokine CCL2 -- drug effects
- Diabetes Mellitus, Type 2 -- metabolism
- Diet, High-Fat
- Diphenylamine -- analogs & derivatives
- Disease Models, Animal
- Extracellular Signal-Regulated MAP Kinases -- antagonists & inhibitors
- Fatty Acids, Nonesterified -- metabolism
- Glucose Tolerance Test
- Hyperlipidemias -- metabolism
- Immunoblotting
- In Vitro Techniques
- Insulin -- metabolism
- Insulin Resistance
- Interleukin-6 -- metabolism
- Lipolysis -- drug effects
- MAP Kinase Signaling System -- drug effects
- Male
- Mice
- Protein Kinase Inhibitors -- pharmacology
- Real-Time Polymerase Chain Reaction
- Receptors, Leptin -- deficiency
- Reverse Transcriptase Polymerase Chain Reaction
- Signal Transduction
- Triglycerides -- metabolism
- Tumor Necrosis Factor-alpha -- drug effects
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.